Appointment of Scientific Advisory Board

The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti is comprised of distinguished experts in preclinical and clinical drug development, diagnostics, and infectious diseases. The SAB will provide scientific and medical expertise as well as strategic guidance to support AUROBAC’s R&D strategy and to help advance its first products to clinical trials. The SAB duties will also include program execution considerations in the framework of innovation, clinical and market dynamics.

Leveraging the invaluable expertise of the SAB, the AUROBAC team is well prepared to advance its product pipeline and provide effective treatments for patients with severe bacterial infections.

Know more